Earnings Call · Q1 FY2026·2026-04-29

Q1 26EPS +6.40%·Rev n/aQ4 25EPS +6.42%·Rev n/aQ3 25EPS +22.72%·Rev n/aQ2 25EPS +52.73%·Rev n/a⚠ consensus missing

REGENERON PHARMACEUTICALS, INC. REGN

Ryan Crowe — Senior Vice President, Investor Relations

Leonard Schleifer — Bd. Co-Chair, President & CEO

George Yancopoulos — Bd. Co-Chair, President & CSO

Marion McCourt — EVP Commercial

Christopher Fenimore — EVP Finance CFO

−6.2%1d on move date−6.2% vs SPY3d−4.1%5d−4.0%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more REGN calls or request research access.

More REGN calls Browse calls Request research access